Immunovant Just Paid $39M to Walk Away From a Drug That Didn't Work

These costs hit Immunovant's R&D line, helping push total research spending to over $456 million for fiscal year 2026, up from about $361 million the prior year. That's a meaningful jump, and a chunk of it went toward a drug the company will never sell.

Immunovant licensed batoclimab from HanAll Biopharma, a South Korean company that originally engineered the antibody. The licensing deal (called the HanAll Agreement) covers the intellectual property for both batoclimab and Immunovant's next-generation candidate. The company has started discussions with HanAll about potentially returning the batoclimab rights, but those talks are still ongoing.

Why FcRn Inhibitors Keep Struggling in Eye Disease

Batoclimab's failure isn't an isolated incident. The broader FcRn inhibitor class has now essentially struck out in thyroid eye disease. Argenx's efgartigimod (sold as Vyvgart) also moved away from TED after underwhelming results. A 2025 expert review put it bluntly: FcRn inhibitors "do not seem to provide an effective therapeutic alternative for active TED."

The mechanism works beautifully in other autoimmune conditions. Vyvgart is approved for generalized myasthenia gravis and CIDP (a nerve disorder). Johnson & Johnson's nipocalimab (IMAAVY) won FDA approval for myasthenia gravis in April 2025, with a pediatric label to boot. The FcRn market is already generating multi-billion-dollar revenues across neuromuscular and hematologic diseases.

But eyes, apparently, are a different story. The autoimmune pathways driving TED seem to involve more than just rogue antibodies. The leading treatment, teprotumumab, works by blocking a completely different target (IGF-1R), and newer drugs in that same class are showing promising results. FcRn blockade alone just doesn't move the needle enough where it counts.

Immunovant's Plan B (and Why It Matters)

With batoclimab dead, Immunovant is going all-in on IMVT-1402, its next-generation FcRn inhibitor. The company is positioning it as a cleaner, more focused bet across a half-dozen autoimmune diseases: Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, Sjögren's disease, and cutaneous lupus.

Top-line data from the difficult-to-treat rheumatoid arthritis study and a proof-of-concept lupus trial are expected in the second half of 2026. Pivotal Graves' disease results should arrive in 2027. Those readouts will determine whether Immunovant's concentrated pipeline strategy was brilliant simplification or a dangerous lack of diversification.

The competitive pressure is real. Argenx is pursuing more than ten autoimmune indications with efgartigimod. J&J is building what it calls a "pipeline in a pathway" with nipocalimab, targeting rare obstetric conditions and blood disorders alongside the neuromuscular staples. UCB's rozanolixizumab (Rystiggo) rounds out the approved FcRn trio. Immunovant needs IMVT-1402 to not just work, but to differentiate itself in an increasingly crowded field.

The Bigger Picture

Batoclimab's demise is a reminder that late-stage failures are brutally expensive, both financially and strategically. Immunovant lost its most advanced clinical asset, burned $39 million just to clean up, and now rides entirely on a drug that hasn't finished a pivotal trial.

For the broader FcRn space, the lesson is nuanced. The mechanism is validated and commercially proven in neuromuscular disease. But "lower the antibodies" isn't a universal fix for every autoimmune condition. TED has now humbled multiple companies that assumed otherwise.

Immunovant's stock story is no longer about a diversified pipeline. It's a binary bet on IMVT-1402. The next twelve months will tell us whether that bet pays off, or whether $39 million was just the opening act of a much more expensive education.

Biogen Spent $5.6B on Apellis. Then It Torched the Science.

Biogen closed its $5.6 billion Apellis acquisition and immediately killed most of the company's research programs, keeping only the two products already making money. It's a pattern that keeps repeating in big pharma M&A, and it says a lot about what acquirers actually value.